anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided are targeted nanoparticles. In certain embodiments, the targeted nanoparticles comprise a nanoparticle and a myeloid cell (MC) targeting moiety stably associated with the outer surface of the nanoparticle. According to some embodiments, the MC targeting moiety is an immunosuppressive myeloid cell (isMC) targeting moiety. In certain embodiments, the targeted nanoparticles further comprise a detectable label (e.g., an  in vivo  imaging agent), a drug, or both. Also provided are compositions comprising the targeted nanoparticles of the present disclosure. Methods of using the targeted nanoparticles to image MCs (e.g., isMCs) and/or to modulate and/or disrupt MCs (e.g., isMCs) are also provided.
972,128. Pellets for ruminant animals. WELLCOME FOUNDATION Ltd. Jan. 12, 1961 [Jan. 21, 1960], No. 2304/60. Heading A5B. Pellets for administering biologically active substances such as hormones, trace elements, antibloat agents, antibiotics, anthelminties and systemic insecticides to ruminant animals are of the type described and claimed in Specification 866,924, i.e. the pellets have a density of at least 2.5 and a weight of at least 1 grm. so that, after administration, the pellet remains relatively permanently in the rumeno-reticular sac of the animal and the active substances are slowly released into the contents of the sac, but are prepared by compressing on to a core 1 containing the biologically active substance by the compression coating technique a high density layer 2 through which is a hole 3 which extends to the core. The hole may extend into the core and the core itself may be produced by compression. The high density layer is largely iron powder and a metallic oxide such as cupric oxide may be present. Conventional diluents, binders and lubricants may also be present.
Some azoles, including posaconazole, have been associated with prolongation of the QT interval on the electrocardiogram. In addition, cases of torsades de pointes have been reported in patients taking posaconazole. 

Results from a multiple time-matched ECG analysis in healthy volunteers did not show any increase in the mean of the QTc interval. Multiple, time-matched ECGs collected over a 12-hour period were recorded at baseline and steady-state from 173 healthy male and female volunteers (18 to 85 years of age) administered Noxafil ® oral suspension 400 mg twice daily with a high-fat meal. In this pooled analysis, the mean QTc (Fridericia) interval change from baseline was –5 msec following administration of the recommended clinical dose. A decrease in the QTc(F) interval (–3 msec) was also observed in a small number of subjects (n=16) administered placebo. The placebo-adjusted mean maximum QTc(F) interval change from baseline was <0 msec (–8 msec). No healthy subject administered posaconazole had a QTc(F) interval ≥500 msec or an increase ≥60 msec in their QTc(F) interval from baseline. 

Posaconazole should be administered with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs that are known to prolong the QTc interval and are metabolized through CYP3A4 [see Contraindications (4.3) and Drug Interactions (7.2)].
Guided growth affects the physis in children to produce a desired effect. Several devices achieve alteration of growth, including staples, plates, and screws. Complications can include device failures, failure to modulate growth as expected, and unintended physeal arrest. We present the results of a unique technique designed to minimize these complications. This was a retrospective review of guided growth at the knee at a single institution utilizing cannulated screws with epiphyseal-entry points. Each case was reviewed to determine the presence of complications related to guided growth, including implant breakage, implant pull-out or pull-through, iatrogenic physeal arrest, failure to modulate growth, and the incidence of revision surgeries. There were 89 patients who had 146 epiphyseal-entry guided growth procedures with a total of 221 4.5 mm cannulated screws. There were no iatrogenic physeal arrests. Five (2.26%) screws in 4 (4.49%) patients had either a broken screw or screw pull-out/pull-through requiring revision procedures. Three patients had osteotomies after skeletal maturity. Four had revision-guided growth for other reasons: 2 due to a lack of timely follow-up, 1 for iatrogenic genu varum without implant failure, and 1 due to recurrent deformity after implant removal. Revision procedures were unanticipated in 6 (6.74%) patients. This study describes a technique for placing cannulated screws at the knee with epiphyseal starting points. Our rate of complications and number of revision surgeries compare favorably with those noted for other techniques. Guided growth using epiphyseal-entry cannulated screws is a safe, effective option for most patients.
Participants allocated to the waitlist control arm will receive a set of pamphlets with generic, knowledge-based dietary and physical activity information. All pamphlets are developed based on the self-management framework. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
This study is a first-in-human, multicenter, open-label, uncontrolled, non-randomized, phase 1a/1b study. The study consists of a dose escalation part and a dose expansion part. In the escalation part, the primary objectives are to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) to establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or maximum administered dose (MAD) of NB002. The expansion part is to further evaluate the safety and tolerability of NB002 at the RDE dose established in the dose escalation part and to explore antitumor activity in the selected population. All subjects will be treated with NB002 via IV infusion at predefined dose levels Q3W on Day 1 of each 21-day Cycle.

The design of the dose escalation part will be provided below. Further details on dose expansion part will be updated later once more information on potentially benefiting tumor types is confirmed.
Preterm birth has become the leading cause of neonatal death and the second leading cause of death among children under five years of age. Preterm childrens are more susceptible to adverse health problems including brain injury and neurodevelopment delay, and are at risk of chronic diseases which could impair the health status and life quality later in life. However, the causes of preterm birth is still not clear, and there are no effective prediction and preventive strategies. The Preterm Birth Cohort Study in Guangzhou (PBCSG) will collect the epidemiological,clinical information and biological specimens including maternal blood,cord blood, placenta, children's blood and stool samples of preterm childrens and their mothers. More importantly, childrens' health status, physical and neurodevelopment will be followed up to late childhood and adolescence. The preterm birth cohort would help to explore the mechanism of preterm birth and to examine the short- and long-term influence of preterm birth on physical health and neurodevelopment of childrens.
BACKGROUND: Strongyloidiasis is a soil-transmitted helminth infection caused by Strongyloides Stercoralis, mostly in tropical and sub-tropical regions, affecting over 600 million people worldwide. Infection is more prevalent among those who are socioeconomically disadvantaged, institutionalized, or residing in rural areas. Parasitic adult females reside in the duodenum or stomach and produce eggs that hatch in the mucosa. Chronic infection may be asymptomatic or be associated with dermatological, respiratory, or gastrointestinal symptoms. The diagnosis of S. stercoralis is often delayed due to the presence of subclinical or poorly symptomatic cases, the usually low parasite load and irregular larvae output, and the lack of a gold standard diagnostic test. We present an unusual case of a 13-year-old female patient with intestinal perforation due Strongyloides Stercoralis infection.
CASE REPORT: We present a 14year old female, who presented with features of acute abdomen and was operated on an account of intestinal perforation due to Typhoid ileitis in a private hospital, due to worsening condition the patient was referred to our Teaching Hospital, where she had laparotomy and small bowel resection due to probably typhoid ileitis not properly managed, the sample was submitted for histopathology test. An area of intestinal ulcers and perforation, adult worm, and ova of parasite lodged within the mucosa and crypts of small intestine consistent with Strongyloides Stercoralis was seen.
CONCLUSION: We report a rare case of intestinal perforation due Strongyloidiasis. In endemic areas, other Neglected Tropical Diseases should also be considered as differential diagnoses of acute abdomen and the associated unusual complications like intestinal perforation.
This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
<P>PROBLEM TO BE SOLVED: To provide an enteral nutrient preparation expectable of an improvement in protein metabolism, immune capacity, intestinal mucous functions, etc., by administration thereof to patients during surgical stress, patients suffering from serious infectious diseases, etc.  <P>SOLUTION: The liquid enteral nutrient preparation comprises the following ingredients A, B, C, D and E as principal ingredients and has 300-600 mOsm/kg osmotic pressure and 100 amino acid score.The ingredient A contains a protein, a glutamine-containing peptide and an amino acid and is a nitrogen source ingredient of10-40% energy% based on the whole energy source. The ingredient B is a lipid of 10-40 energy% based on the whole energy source. The ingredient C is a glucide of 40-80 energy% based on the whole energy source. The ingredient D is an emulsifying agent. The ingredient E is water.  <P>COPYRIGHT: (C)2004,JPO
Methods and systems for analyzing care data are described. The method includes building a virtual model of a physical medical device. Training is provided to a patient associated with the physical medical device to properly use the physical medical device by manipulating the virtual model. First care data associated with a first sensor associated with the physical medical device and second care data associated with a second sensor is received by a cloud service. The cloud service analyzes the first care data to obtain a first care data score and analyzes the second care data to obtain a second care data score. The cloud service scores, using a machine learning algorithm, the first care data score and the second care data score to obtain a combined care score. The cloud service determines whether the combined care score is greater than a threshold. The cloud service triggers an emergency procedure when it is determined that the combined care score is greater than the threshold.
BACKGROUND: Globally, liver cancers are the second most lethal malignancy after lung cancer (0.83 million deaths in 2020). Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer and is typically associated with liver fibrosis or cirrhosis. HCC diagnosis relies on histologic examination of surgical specimens or conventional tissue biopsy material. However, standard tissue biopsies are invasive and often do not accurately reflect the tumor heterogeneity. On the other hand, the use of liquid biopsies, represented mainly by circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), has greatly increased in the past 2 decades. Indeed, liquid biopsies are a noninvasive, repeatable, and sensitive approach to studying tumor biology.
CONTENT: This review describes current clinical applications of ctDNA analysis in the management of patients with chronic liver disease, cirrhosis, and HCC. There is a substantial clinical potential of ctDNA, but interventional studies are still lacking for the moment.
SUMMARY: Detection of ctDNA in both asymptomatic individuals and high-risk patients (with chronic liver disease or cirrhosis) contributes to the early diagnosis of HCC. ctDNA analysis also offer tremendous information on the tumor burden and on the risk of early recurrence. The implementation of ctDNA analysis, in association with classical tumor markers (e.g., alpha-fetoprotein), may improve (a) HCC screening in high-risk patients, (b) stratification of the recurrence risk after surgery, and (c) prognosis evaluation of patients with HCC.
In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
The invention relates to an oral medicament for treating insomnia according to the traditional Chinese medical science. According to the traditional Chinese medical science, insomnia belongs to 'sleeplessness', 'poor sleep', 'incapability of supination' and the like, and is a common clinical symptom. Insomnia refers to difficulty in sleeping, easiness in becoming awake during sleeping, early wake, poor sleeping quality and remarkable reduction in the sleeping time. Long-term insomnia causes a series of clinical symptoms and further induces certain mental and body diseases. According to a large quantity of clinical practices, an oral medicament for treating insomnia according to the traditional Chinese medical science is selected. The medicament has a remarkable curative effect on insomnia caused by heart-kidney insufficiency and deficiency of yin-fluid and blood, and takes effect within 3-4 days.
Tonsillectomy is one of the most frequent surgical interventions in otorhinolaryngology. This surgical is always accompanied by the development of reactive inflammatory phenomena and pain syndrome. The effectiveness and safety of tonsillectomy can be improved through the use of topical treatment in the postoperative period, including antiseptics in the form of a spray. An observational study was conducted at the Department of Otorhinolaryngology of the Russian University of Medicine of the Ministry of Health of the Russian Federation, the purpose of which was to evaluate the clinical efficacy, tolerability and safety of Viroxynol for oral and throat mucosa in patients after tonsillectomy. As a result of the analysis of the data obtained, it was found that the use of Viroxynol for the mucous membrane of the oral cavity and throat in the treatment of patients in the early postoperative period causes a pronounced clinical effect, reduces the need for additional medications, allows faster reduction of pain syndrome against the background of relief of reactive inflammatory phenomena, improves the quality of life of patients, accelerates the healing process, reduces the risk of bacterial inflammation. The drug may be recommended for use in patients after tonsillectomy.
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in adults occurring in a background of cirrhosis. Peritoneal dissemination of HCC is an unusual presentation with an incidence of 2%-16%. Peritoneal metastasis of an unruptured HCC is extremely uncommon. Despite low yield, ascitic fluid cytology serves as a valuable tool for diagnostic evaluation in a patient of cirrhosis with suspicion of malignant transformation. We present a rare case scenario in an elderly female with cirrhosis where the diagnosis of peritoneal metastasis was established on ascitic fluid cytology and confirmed by immunocytochemistry. This report illustrates the unique clinical presentation of an unruptured HCC with its cytological features and a brief review of literature.
Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
This will be the first ever evaluation of a highly scalable and low-cost social support intervention for patients with diabetes delivered entirely via mobile phones. TExT-MED FANS (Trial to Examine Text-based mHealth for Emergency Department Patients With Diabetes With Family And Friend Network Supporter) will unite the benefits of mHealth (scalability, ease of access) and social support interventions (personalized motivation, emotional support). The Diabetes FANS text message based curriculum will make it easier for friends and family to become supporters. Additionally, augmenting TExT-MED with the FANS social support module will be more effective than TExT-MED alone. The personalized support of TExT-MED FANS will also be more effective than providing TExT-MED in combination with a community health worker supporter who lacks a pre-existing relationship with the patient. Through this innovative combination, I can create a more cost-effective and diffusible mHealth solution that maintains the personal connection of social support interventions. To date there has only been one study evaluating social support interventions for patients with diabetes using mHealth, but in this study participants were paired with other subjects with diabetes (not friends or family) and it required intensive face-to-face support group time. TExT-MED FANS will provide key insights into the utility of combining social support interventions delivered solely via mHealth in low-income Latino patients. These insights will help future interventions achieve maximal impact on diabetes and other chronic disease management.
The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
Cancer-related lymphedema represents one of the major complications of cancer treatment, especially for breast and gynecologic cancers. Moreover, it has high impact on cancer survivors and healthcare systems. Lymphedema management still remains challenging. The better understanding of lymphedema physiopathology as well as the development of sophisticated surgical and diagnostic techniques have led to effective strategies to address lymphedema patients but, despite the considerable interest in international literature, no consensus exist. The combination of LVA and liposuction may represent an effective strategy in treating patients with cancer-related lymphedema, in order to reach a significant decrease in volume and reduction of lymphangitis rate as well as stable results in time. In addition, it has the aim of being minimally invasive and well tolerated by patients
A. Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels. B. Melphalan (70 mg/m2/day) administered on days -6 and -5. C. Fludarabine (25 mg/m2/day) administered on days -6, -5, -4, -3, -2. All patients receiving matched related or unrelated donor allografts receive anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2 to deplete chemotherapy resistant host T-cells that could hinder engraftment, and it may provide additional GVHD prophylaxis.
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptorbody which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention further provides for a ligandbody which specifically binds TIE-2 receptor. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth, differentiation or migration of cells expressing the TIE-2 receptor, including, but not limited to, hematopoietic precursor cells, a method of blocking the growth, differentiation or migration of cells expressing the TIE-2 receptor including, but not limited to, hematopoietic precursor cells, and a method of attenuating or preventing tumor growth in a human.
Preterm birth is the main reason of perinatal morbidity and mortality. The main management method of this important problem is to prolong the pregnancy period and to use corticosteroids to prevent fetal pulmonary distress. The most widely studied tocolytic agents, ritodrin, salbutamol and terbutaline are all betamimetics, and they are shown to prolong birth labor till 7 days and do not have any effct on the fetal mortality. However, their maternal side-effects are inevitable and can be mortal. They cause tachycardia, hypotension and some biochemical disturbances. Furthermore, maternal death is possible due to pulmonary edema. These adrenergic agonists are the first line tocolytics, but calcium canal blockers are becoming more popular since they have less side effects and comparable efficacy.

Calcium canal blockers are nonspecific smooth muscle relaxants used in adult hypertension treatment. Their tocolytic effect depends on their inhibition of calcium ions into the myometrial cells. In vitro studies have shown that they have strong relaxant effects on human myometrium. In the present study, our aim is to investigate the effects of nifedipine in our clinic in a period between 2002 and 2005, when it was first used in our clinic as the sıngle tocolytic agent. Its success in preventing preterm labor and its complications in our earlier practice will be noted and this retrospective study will guide us in its current usage, dosages and side-effects.
PURPOSE:To obtain a liquid nasotracheal pharmaceutical preparation, containing DL- or L-threo-3-(3,4-dihydroxyphenyl)serine as an active ingredient and stably suppliable into the blood without being affected by the stafe of the digestive tract. CONSTITUTION:The nasotracheal pharmaceutical preparation is formulated by comprising (1) DL- or L-threo-3-(3,4-dihydroxyphenyl)serine (hereinafter abbreviated to threo-DOPS), (2) a phospholipid, saponin, bile acid, glycyrrhetinic acid or a derivative thereof and (3) ascorbic acid, tartaric acid, citric acid, aspartic acid or a salt thereof and regulating the pH to 4-6. The amounts of the ingredients based on 10 ml pharmaceutical preparation are 50-400mg threo- DOPS, 50-400mg ingredient (2), e.g. glycyrrhetinic acid-3-O-monohemiphthalate and 25-200mg ingredient (3), e.g. sodium ascorbate. The preparation has low irritancy to the nasal mucous membrane and can be administered for a long period by a painless method. Since the norepinepherine level in the cerebrospinal fluid is increased, the treatment of Parkinson disease by the instilling administration of nasal drops can be carried out.
Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.